Potential conflict of interest: Nothing to report.
Serum Golgi Phosphoprotein 2 level: A better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma†
Article first published online: 17 APR 2009
Copyright © 2009 American Association for the Study of Liver Diseases
Volume 50, Issue 1, page 325, July 2009
How to Cite
Li, X., Wu, K. and Fan, D. (2009), Serum Golgi Phosphoprotein 2 level: A better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma. Hepatology, 50: 325. doi: 10.1002/hep.23028
- Issue published online: 23 JUN 2009
- Article first published online: 17 APR 2009
- Accepted manuscript online: 17 APR 2009 12:00AM EST
To the Editor:
We read with interest the article by Riener et al.1 reporting the potential usefulness of Golgi Phosphoprotein 2 (GOLPH2) as a new serum biomarker for diagnosing hepatocellular carcinoma (HCC). We would like to draw attention to similar studies on the use of serum GOLPH2 in the differentiation of HCC patients from controls with no liver disease and patients with cirrhosis. GOLPH2 was originally described as a resident Golgi type II transmembrane protein expressed primarily in epithelial cells of many human tissues.2 In the normal human liver, GOLPH2 expression was found in biliary epithelial cells, but it was barely detectable in hepatocytes. However, expression of GOLPH2 was found to be strongly up-regulated in hepatocytes from patients with viral and nonviral liver diseases.3 A recent study showed that GOLPH2 was detected in human serum, and it was found to be elevated in the serum and tissue in the woodchuck model of HCC in comparison with the nonneoplastic liver.4 Thus, GOLPH2 may be a potential marker for the early detection of HCC.
We tested the serum GOLPH2 levels in patients with HCC (50), patients with cirrhosis (50), and controls with no liver disease (50). Our results showed that GOLPH2 was detected in the sera of all patients, but the levels were higher in patients with HCC and cirrhosis in comparison with controls with no liver disease. Median serum GOLPH2 levels were 1.35 relative units (range, 0.52–12.99) in controls with no liver disease, 4.39 relative units (range, 0.52–26.78) in patients with cirrhosis, and 14.37 relative units (range, 1–57) in those with HCC (P < 0.0001 for HCC versus patients with cirrhosis and controls with no liver disease). Median serum alpha-fetoprotein (AFP) levels were 2.46 ng/mL (range, 1.15–7.68) in controls with no liver disease, 6.11 ng/mL (range, 0.28–625) in patients with cirrhosis, and 16.2 ng/mL (range, 0.89–352,000) in HCC patients (P < 0.0001 for HCC patients versus controls with no liver disease and patients with cirrhosis). When patients with cirrhosis were compared to those with early HCC (United Network for Organ Sharing modified tumor-node-metastasis stages 1 and 2), the median serum GOLPH2 levels were significantly higher in those with early HCC: 12.69 relative units (range, 1–49) versus 4.39 relative units (range, 0.52–26.78) in patients with cirrhosis (P < 0.0001). Median serum AFP levels were also significantly higher in patients with early HCC than in those with cirrhosis: 11.23 ng/mL (range, 1.48–137,000) versus 6.11 ng/mL (range, 0.28–625) in patients with cirrhosis (P < 0.001). However, when we evaluated the sensitivity and specificity of GOLPH2 in patients with early HCC versus those with cirrhosis, the results showed that GOLPH2 (sensitivity, 62%; specificity, 88%) was significantly better than AFP (sensitivity, 25%; specificity, 97%; P < 0.0001).
In summary, our data highlight three points. First, we have shown that GOLPH2 is a better marker than AFP for diagnosing early HCC, partially concurring with the findings from Riener et al.'s study. Second, the sample size is not large enough, so we could not establish the performance of GOLPH2 according to the etiology of the underlying liver disease. Third, before this marker can be applied clinically, multicenter cohorts of validation are still needed.
- 1Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. HEPATOLOGY. doi:10.1002/hep.22843., , , , , , et al.
- 2GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 2000; 249: 53–65., , , , , , et al.
- 3Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. HEPATOLOGY 2002; 35: 1431–1440., , , , .
- 4Use of targeted glycoproteins to identify serum glycoproteins that correlated with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 2005; 102: 779–784., , , , , , et al.
Xiaohua Li Ph.D.*, Kaichun Wu Ph.D.*, Daiming Fan Ph.D.*, * Xijing Hospital of Digestive Diseases, Xi'an, China.